Core Technology

MVC utilizes mammalian cell-culture technology to develop and manufacture viral vaccines and biosimilars. Unlike traditional egg-based production platform, cell culture technology offers the following advantages in production, safety and quality:
 

  • Reduce the risk of cross contamination and cost of CIP by using disposable bioreactors.
  • Prevent transmissible spongiform encephalopathies (TSE) by using serum free media.
  • Maintain constant material supplies
  • Expedite scale-up production
  • Offers diverse cell-based biologics from vaccines to antibodies
Our Vaccine Manufacturing Facility
  • Located in Hsinchu Biomedical Science Park.
  • Taiwan’s first multipurpose cell-based vaccines and biologics production facility complied with PICS/ GMP standard.
  • The production area is located on the first floor, including 2 independent production lines to manufacture antibodies and vaccines certified to biosafety level 2+.
  • The plant also includes an aseptic fill-finish line for PFS and vials.